RMC No. 72-2023: Updated VAT-Exempt Medicines List for Cancer, Diabetes, Hypertension and Other Conditions

RMC No. 72-2023 updates the VAT-exempt medicines list, affecting cancer, diabetes, hypertension and other medicines sold by healthcare businesses. Pharmacies, hospitals, clinics, medicine distributors, and VAT-registered healthcare businesses must immediately review whether their medicine master lists, point-of-sale systems, invoices, and tax coding reflect the latest FDA-endorsed updates to the VAT-exempt medicines list. RMC No. 72-2023 […]

RR No. 25-2018: VAT Exemption on Diabetes, High Cholesterol, and Hypertension Medicines Starting January 1, 2019

RR No. 25-2018 exempts FDA-listed diabetes, cholesterol, and hypertension medicines from VAT on local sale starting January 1, 2019. Starting January 1, 2019, businesses selling covered medicines for diabetes, high cholesterol, and hypertension must treat qualified sales as VAT-exempt, but only if the drug or medicine is included in the official VAT-exempt list identified and […]